Although efforts at the preclinical level to develop AZD-1775, a potent, small-molecule inhibitor of Wee1 [119,120], in AML have focused largely on using it to circumvent resistance to cytarabine [121,122], a sound rationale exists for combining this agent with HDACIs in AML. This evidence concerns the gene WEE1 and acute myeloid leukemia.